Dr Liz Meehan

Liz has a degree in Polymer Science and Engineering, a PhD in Adhesion Science and is a material scientist with over 30 years industrial experience. She has worked in the Pharmaceutical Technology & Development function of AstraZeneca since 2003. She joined as an Associate Principal Scientist in Polymer Science focussed on developing a deeper understanding of structure-property relationships for polymeric excipients linked to excipient functionality in pharmaceutical dosage forms. In 2000 as an Associate Principal Scientist in Material Science she broadened her remit to include material properties of API, excipients and intermediates and their impact on drug product process and performance. In 2014 she progressed to Principal Scientist in Material Attributes and Product Performance and she currently has responsibility for the developent of materials control strategies in drug product development to deliver robust pharmaceutical products and processes. She has worked on a variety of drug development projects involving a wide range of formulations and processes. She also has a responsibility to support materials science aspects of marketed pharmaceutical products throughout product life cycle management.

For project REMEDIES (https://remediesproject.com/research-2/project-structure/app-b/), a consortium based industrial research project funded through AMSCI (Advanced Manufacturing Supply Chain Initiative), Liz leads the sub-project on Primary to Secondary pharmaceutical processing. She is also a main board member of the International Pharmaceutical Excipients Council (IPEC) for Europe (http://ipec-europe.org/).